Xilio Therapeutics, Inc. Annual Report - How They Did This Year (2025)

Hey there! Thinking about Xilio Therapeutics and what they've been up to? This guide is for you. We'll break down their past year (2025) in plain English. You can easily understand what's going on. Then decide if it fits your investments. Think of it as chatting with a friend, not reading a stuffy report.

Here's what we'll cover, piece by piece:

1. What does this company do and how did they perform this year? Xilio Therapeutics is a biotech company developing drugs. They focus on new cancer treatments. These treatments activate the immune system inside tumors. They aim to spare healthy tissues. This past year (2025), they formed important partnerships. These alliances help advance their drug projects. They signed agreements with major drug companies. These include Gilead Sciences Inc. (starting 2024) and AbbVie Group Holdings (starting 2025). They also partnered with F. Hoffmann-La Roche Ltd. for clinical supplies (2024 and 2025). Xilio also has ongoing agreements with Wuxi Biologics for manufacturing. They work with City of Hope for intellectual property. These partnerships are a big deal. They bring in money, expert knowledge, and manufacturing help. This is crucial for a biotech company. Xilio is still developing drugs and has no products for sale. Their main focus is advancing research and development. This includes lab tests and human trials for their main drug candidates. They want to get potential new treatments ready for patients.

2. Financial performance - revenue, profit, growth metrics As a biotech company developing drugs, Xilio sells no products yet. Its income mainly comes from partnerships and grants. Xilio actively spends money on Research and Development (R&D). They also spend on General and Administrative (G&A) costs. This is normal for a biotech company creating new drugs. They are heavily investing to get treatments through testing. They also need regulatory approval. Xilio has been losing money since it started. They expect to keep losing money for the foreseeable future. This funds their many research projects. This is common for biotech companies. They invest a lot in research and human trials. They do this before selling any products. To fund these efforts, they actively raised money. In 2024, they sold shares directly to certain investors. They also sold shares gradually into the stock market. This minimized price impact. They secured stock purchase agreements with Gilead. This provided more money. For 2025 and beyond, they plan to sell more shares in June 2025. This will raise more money. They also have another stock purchase agreement with AbbVie. They could receive up to $36.2 million more cash. This would happen in late 2026. It depends on investors using their Series C common stock warrants. These warrants were part of their June 2025 offering. Investors can use them at $10.50 per warrant. This continuous fundraising shows their strategy. They want to keep enough money to operate. This supports their drug development projects.

3. Major wins and challenges this year

   • Major Wins: The biggest wins are their partnerships. They teamed up with drug giants like Gilead and AbbVie. These deals are not just about money. They show that Xilio's science and potential drugs are promising. Industry leaders validate their work. Securing an agreement with Roche for trial supplies is also positive. It shows their programs are progressing. They now need materials for human trials. Successfully getting money through various offerings was also a big success. It ensures they have cash for research and human trials. The potential $36.2 million from warrant exercises in 2026 is another positive sign. It indicates future funding.
   • Challenges/Things to Watch: A big challenge was the 1-for-14 reverse stock split. This happened on March 13, 2026. This was shortly after the 2025 financial year ended. A reverse stock split reduces the number of available shares. For example, 14 old shares became 1 new share. It typically increases the price per share proportionally. Companies usually do this when their stock price is very low. They often need to meet minimum price rules. This helps them stay listed on exchanges like Nasdaq. This suggests their stock has done poorly. They risked being removed from the exchange. Delisting would make shares hard to buy or sell. It would also hurt the stock price and investor trust. The company itself notes this split might not work. It could still negatively affect the stock price. The constant need for money also highlights a challenge. They are a biotech company still developing drugs. They don't sell many products yet. They rely heavily on outside funding. The stock option repricing in November 2025 also fits here. Companies often do this to keep employees motivated. This happens when the stock price drops a lot. It makes their original stock options worth less.

4. Financial health - cash, debt, liquidity Xilio clearly focuses on staying financially healthy. They actively get money to fund their operations. Selling shares directly, stock agreements with Gilead and AbbVie, and planned future offerings are key ways they get cash. The potential $36.2 million from investors using their warrants in late 2026 provides a specific future cash source. They also have "restricted cash." This means some cash is set aside by rules or agreements. It's for specific purposes, like security for leases. This cash is not immediately available for daily operations. Consistently raising funds suggests they manage their money well. They ensure they have enough to operate. This supports their research projects. However, their risk factors explicitly state they "will need to obtain substantial additional capital in the future." This highlights an ongoing and critical challenge. As of June 30, 2025, the value of their publicly traded shares was about $34.9 million. This is relatively small for a public company. It can lead to big swings in the stock price. After the 1-for-14 reverse stock split, they had 5,782,511 shares available. This was as of March 18, 2026. This lower share count and small total company value show Xilio is still early in its life as a public company.

5. Key risks that could hurt the stock price

   • Financial Survival: The company explicitly states they will need "a lot more money in the future." This means they will constantly seek more funding. If they cannot get it easily or cheaply, it could seriously hurt their ability to operate. It could also stop them from moving their drugs forward. They have been losing money since they started. They expect to keep doing so for a long time. This makes continuous funding absolutely critical.
   • Delisting from Nasdaq: This is a very serious and immediate risk. The company explicitly states they could be "delisted" from Nasdaq. This would happen if they "fail to meet Nasdaq's rules to stay listed." This is the main reason for the 1-for-14 reverse stock split. Delisting would make it much harder for investors to trade shares. It would also make shares hard to buy or sell. This could severely hurt the stock price and investor trust.
   • Drug Development is a Marathon, Not a Sprint (and it's risky!): Xilio's entire business depends on successfully developing its potential drugs. These drugs are still very early in development. There's a big risk their unique technology might not work. It might not be safe in human trials. Their early lab tests might not move to human trials. Even if they reach human trials, there could be major delays. Trials might be stopped due to safety or not working well enough. Like all drugs, their candidates could have unexpected or severe side effects. Also, early trial data can change. More complete information might become available. This can mislead investors.
   • Reliance on Others: They rely heavily on other companies for much of their work. This includes manufacturing (like WuXi Biologics in China). Problems with politics or getting supplies there is a risk. They also rely on others to run complex human trials. They plan to combine their drugs with other companies' drugs. This means they have less control over those parts and their availability. If partners or suppliers don't perform well, it could seriously slow down Xilio's drug development.
   • Competition & Intellectual Property: The biotech world is very competitive. Other companies might develop similar or better drugs faster. Competitors might have more money, technology, and people. Protecting their ideas (patents) is also crucial. If they can't get or keep strong patents for their technology and drugs, competitors could copy their work. This would severely hurt their ability to make money later.
   • Regulatory Hurdles: Even if a drug looks promising, getting government approval is long and expensive. It's also highly uncertain. There's no guarantee any of their drugs will ever get approved and reach the market.
   • Stock Price Rollercoaster: Beyond the company's performance, the stock price itself can swing up and down a lot. Sometimes this happens for reasons unrelated to the company. These include overall market changes or how investors feel about biotech. The reverse stock split might not fix this volatility. It could even make investors feel even worse.

6. Competitive positioning Xilio attracts partnerships with major drug companies like Gilead and AbbVie. This suggests they have exciting science or promising drugs. These stand out in the competitive biotech field. These partnerships give Xilio an advantage. They get more money, expert knowledge, and market access. This is compared to smaller companies without partners. Their focus on tumor-selective immune cancer treatments shows a specialized approach. This is within the cancer treatment field. They are also classified as a "Smaller reporting company" and an "Emerging growth company." These are under SEC rules. This means they are still relatively small and growing. They have less paperwork and lower costs to follow rules. This status offers some operational flexibility. But it also highlights their early stage of development.

7. Leadership or strategy changes Leadership clearly focuses on forming partnerships. They also actively get money. This shows a sustained strategy. They want to move their drugs forward through outside help and funding. The reverse stock split and stock option repricing were challenging events. But leadership likely saw them as strategic moves. They aim to keep and motivate important employees. They also want to stay listed on the stock exchange. This is especially true when the stock price is falling. These actions reflect management's efforts. They navigate difficult market conditions. They also work to ensure the company can survive long-term.

8. Future outlook Xilio's future outlook seems tied to its partnerships. It also depends on its ability to fund its many research projects. Agreements with Gilead, AbbVie, Roche, Wuxi Biologics, and City of Hope extend into 2025 and beyond. This indicates a busy period of continued drug development. This includes lab and human trials. They also plan to get more money in the future. This includes the potential $36.2 million from investors using their warrants in late 2026. This shows a forward-looking approach to financial stability. Their forward-looking statements emphasize their plans. They want to start more human trials. They aim to secure more funding. They plan to move their potential drugs through different development steps. Eventually, they want to sell any drugs that get approved. However, remember their future is tied to overcoming many risks. These include the continuous need for a lot of money. There are also high risks and long waits in drug development and government approval.

9. Market trends or regulatory changes affecting them As a biotech company developing drugs, Xilio faces changing rules. These rules govern drug development. They also face intense competition in the drug industry. Their annual report notes they are impacted by "current or future government rules." These relate to drug approval, pricing, and healthcare policy. They are also affected by "general economic conditions." This includes inflation and new or changed taxes on international trade. For example, inflation can increase research and development and manufacturing costs. Trade tariffs could impact how they get supplies. This is especially true with partners like WuXi Biologics in China. Being an "Emerging growth company" under the JOBS Act helps them. They benefit from less paperwork. They also follow different accounting rules. This saves money on office work. It lets them focus resources on drug development.